baber/WOPTO huggingface dataset:
Patent NZ-552181-A (NZ)
Title: Combination of acetaminophen and ibuprofen
Inventor: ATKINSON HARTLEY CAMPBELL
Filed: 2004-07-07
Abstract: Disclosed is a combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol. Also disclosed is a pharmaceutical combination composition suitable for the treatment of pain, the composition including paracetamol and ibuprofen in a ratio range of from 47.5:12.5 to 50:15 suitable for providing synergistic pain relief.
Patent NZ-556026-A (NZ)
Title: Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain
Inventor: SCHMUTZ MARKUS
IPC: A61P25/28
Filed: 2002-11-11
Abstract: Disclosed is a use of a compound of formula (I) for the manufacture of a medicament for the treatment of a disorder, which disorder is selected from the group consisting of affective disorders, attention disorders, hyperalgesia associated with neuropathic pain, herpetic neuralgia, diabetic neuropathic pain, migraine, causalgia and deafferentation syndromes.
Patent NZ-556530-A (NZ)
Title: Method and apparatus for the preparation of biodiesel
Inventor: BROCKETT GARY
IPC: C10L1/00
Filed: 2007-07-16
Abstract: A method of preparing biodiesel from a source of oil or fat is disclosed, wherein the production process including the step of: combining a volume of a dehydrated source of oil or fat with a volume of short chain alcohol in a vessel in the presence of a concentration of an acid catalyst at a temperature of between about 20 Deg. C and 140 Deg. C for a time sufficient to provide a combined volume where at least some of the fatty acid content of the source of oil or fat is converted to alkyl esters; wherein the method additionally includes at least one of the following steps: aerating the volume of oil or fat in a vessel at a temperature of between about 20 Deg. C and 140 Deg. C for a period sufficient to provide a substantially dehydrated source of oil or fat and a vapour laden air stream; and aerating the combined volume in a vessel at a temperature of between about 20 Deg. C and 140 Deg. C for a period sufficient to reduce the amount of short chain alcohol in the combined volume, providing a dealcoholised combined volume and an alcohol laden air stream. Preferably, the temperature during said steps of the process is maintained between about 50 Deg. C and 70 Deg. C, and particularly at about 60 Deg. C.
Patent NZ-560320-A (NZ)
Title: Quinoxaline derivatives as antitumor agents
Inventor: BECKLIN ROBERT R
IPC: A61K31/495
Filed: 2006-01-25
Abstract: Disclosed are quinoxaline compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein W is a piperidine or a piperazine moiety and the rest of the substituents are disclosed within the specification. Also disclosed is the use of the said compound in the manufacture of a medicament for treating cancer in a mammal.
Patent NZ-563932-A (NZ)
Title: A container and a fitting for a container
Inventor: VOCKLER RODNEY ALAN
IPC: B44D3/12
Filed: 2006-05-17
Abstract: A spout assembly 14 for a container, the assembly 14 having an outer rim 50 and comprising a web 80 extending between spaced portions of the assembly 14, an inner spout 70 formed in the web 80 and having a pouring cusp adjacent the rim 50, and an outer spout 68 formed by a wall 74 that projects above the level of the rim 50 and extends around the web 80 adjacent to the rim 50 on opposite sides of the pouring cusp.
Patent NZ-564991-A (NZ)
Title: Multiplexed polymerase chain reaction for genetic sequence analysis
Inventor: MALANOSKI ANTHONY P
IPC: C12P19/34
Filed: 2006-06-09
Abstract: A PCR method that comprises the steps: (1) extracting nucleic acids from a clinical sample obtained from an organism to produce a target sample containing background DNA of the organism and suspected of containing one or more pathogen nucleic acids from a predefined set of pathogens; (2) adding to the target sample plurality of PCR primers corresponding to genes found in the predefined set of pathogens; (3) performing a polymerase chain reaction on the combined target sample and PCR primers to amplify subset of the nucleic acids that correspond to the genes to produce an amplified sample; The primers include at least one primer pair for each pathogen and comprise a tail sequence that is non-complementary to the DNA of any of the predefined set of pathogens and to the DNA of the species of the organism. The concentration of at least one primer in the polymerase chain reaction is no more that about 100 nM. The tail sequence can be SEQ ID NO: 1 or SEQ ID NO: 2.
Patent NZ-566925-A (NZ)
Title: Hot mix apparatus, typically as vehicle, with rotor sweeping space and allowed to float vertically by non-circular section shaft
Inventor: TRIMBORN HERBERT JOHANN
IPC: B01F27/906
Filed: 2006-09-22
Abstract: Apparatus is disclosed for preparing a hot mix, comprising aggregate and bitumen, for repairing pot holes in roads. A vessel (16) is mounted, vertically disposed, on a vehicle (10) and comprises a mixing chamber (42) in which the aggregate and bitumen are mixed by a paddle assembly (50) mounted on a shaft (60) that rotates about a vertical axis. The shaft is mounted in bearing assemblies (not shown) located at the top and bottom of the mixing chamber. The shaft is able to slide vertically in the upper bearing assembly to cope with thermal expansion as the vessel is heated during the mixing, by virtue of a non-circular cross-sectional shaft sliding in axially fixed restraints. The vessel has a manhole (120) at its upper end (36) through which the aggregate and lumps of bitumen, at ambient temperature and hi solid form, can be loaded into the mixing chamber. The aggregate is loaded first and heated to expel moisture before the bitumen is loaded. The vessel can be tilted to discharge the hot mix through a second manhole (122) located adjacent the bottom of the mixing chamber. The paddle assembly sweeps out the space between the side and the inner part of the rotor, typically due to non-symmetrical placing of vertical plates.
Patent NZ-567944-A (NZ)
Title: Secure digital recording
Inventor: HOLMES NEIL ANTHONY
IPC: G11B27/36
Filed: 2003-03-19
Abstract: A secure digital interview recording apparatus comprises at least one recording deck. Each recording deck includes at least one digital recording drive for recording on at least one digital recording medium. Each recording deck provides means for finalising a recording on said digital recording medium; and a controller for controlling the at least one recording deck. The controller in use prevents removal of said recording medium from the recording drive unless said recording medium has been finalised.
Patent NZ-570001-A (NZ)
Title: Device for sorting disk bodies
Inventor: YAMAGISHI RYOJI
IPC: A63F5/04
Filed: 2007-02-16
Abstract: A device 1 for checking a coin or token, comprising a main plate 2 and a gate plate 3 which is supported rotatably about a shaft 8 and covers openably the main plate 2, characterized in that a gate plate biasing means is disposed at plural positions to apply a biasing force to the gate plate 3 in a direction to close the main plate 2 while the gate plate 3 is reaching a predetermined turning angle about the shaft 8 and to apply a biasing force to the gate plate 3 in a direction to open the main plate 2 when the gate plate 3 is turned by the predetermined turning angle or more.
Patent NZ-570230-A (NZ)
Title: U-shaped disc-shunt and delivery device implantable in the disc of a spine to enable nutrient exchange
Inventor: YEUNG JEFFREY E
IPC: A61B17/06
Filed: 2007-02-05
Abstract: A U-shaped disc shunt (126) is disclosed. The intervertebral disc contains no blood vessels. Nutrients and waste are diffused mainly through adjacent vertebral bodies. As we age, calcified layers form between the disc and vertebral bodies, blocking diffusion. The disc begins to starve and flatten. The weight shifts abnormally from disc to the facet joints causing strain and back pain. Under anaerobic conditions, lactic acid is produced causing acidic irritation and unspecific pain. A U-shaped disc shunt (126) is delivered into and sealed within the degenerated disc (100) simply by needle (101) puncturing and withdrawal, to draw nutrients from bodily circulation into the avascular disc. A continual supply of nutrients increases biosynthesis of the water- retaining sulfated glycosaminoglycans, hence swelling pressure within the disc. The weight is re-shifted from the facet joints to the regenerated disc, alleviating back pain. With oxygen transported through the shunt, anaerobic production of lactic acid is minimized. In addition, the residual lactic acid is expelled through the U-shaped shunt during disc compression into bodily circulation to alleviate unspecific pain.
Patent NZ-574424-A (NZ)
Title: Synthetic bone material comprising collagen and calcium phosphate
Inventor: LYNN ANDREW
IPC: A61L27/20
Filed: 2007-08-10
Abstract: A process for the preparation of a synthetic bone composite biomaterial. The process comprises: - Providing a solid component that comprises one or more of collagen, a glycosaminoglycan (GAG), albumin, hyaluronan, chitosan and synthetic collagen and optionally an inorganic material. The solid component has a surface that is porous; - Providing a fluid composition that comprises one or more of collagen, a GAG, albumin, hyaluronan, chitosan and synthetic collagen and optionally an inorganic material; - Contacting the fluid composition with the solid component; - Cooling the fluid composition to a temperature at which the liquid carrier transforms into solid crystals or particles; and - Removing at least some of the solid crystals or particles by sublimation and/or evaporation. The inorganic material is typically a calcium phosphate material such as brushite, octacalcium phosphate and apatite.
Patent NZ-577699-A (NZ)
Title: Acid Cleaning Composition of citric, glycolic and oxalic acids
Inventor: YERITSYAN KAREN
IPC: C07C55/06
Filed: 2010-06-16
Abstract: Disclosed is an acid cleaning composition in the form of a stable liquid concentrate, wherein the concentrate is made up of acids and wherein of the total acids at least 50 percent by weight comprise: (a) is glycolic acid which is present in amounts of 35-70 percent by weight of total acids; (b) citric acid which is present in amounts of 25-37 percent by weight of total acids; and (c) oxalic acid which is present in amounts of 10- 15 percent by weight of total acids.
Patent NZ-579125-A (NZ)
Title: Scanning mechanisms comprising drive mechanism for imparting rotational motion to imaging conduit
Inventor: COURTNEY BRIAN
IPC: A61B1/045
Filed: 2008-01-21
Abstract: Disclosed is an imaging probe (31) comprised of a hollow shaft, a rotatable conduit, a movable member (70) and an imaging assembly (30). The rotatable conduit extends through the hollow shaft and defines a longitudinal axis. The rotatable conduit is connectable to a rotational drive mechanism for adjusting its angular velocity about the longitudinal axis. The imaging assembly (30) is attached to the rotatable conduit at a location remote from a proximal end of the rotatable conduit. The rotatable conduit is configured to deliver energy to the imaging assembly (30). The imaging assembly includes a movable member (70) for delivering an energy beam along an energy beam path from said movable member (70) out of the hollow shaft at a variable imaging angle to the longitudinal axis. The movable member (70) is mounted so that the variable imaging angle between the beam path and the longitudinal axis is varied by adjusting the angular velocity of the rotatable conduit. A restoring mechanism (76) associated with the movable member (70) is also provided. The restoring mechanism (76) is for orienting the movable member (70) in an orientation relative to the rotatable conduit. This orientation constitutes an original imaging angle occurring in the absence of rotation of the rotatable conduit.
Patent NZ-579787-A (NZ)
Title: Nucleic acids encoding amino acids sequences of gigantea (GI) which is involved in the control of the flowering of plants
Inventor: KARDAILSKY IGOR
IPC: A01H5/00
Filed: 2004-05-14
Abstract: Disclosed is a substantially purified or isolated nucleic acid or nucleic acid fragment from a Lolium species encoding a GIGANTEA (GI) polypeptide, or complementary or antisense to a sequence encoding GI, said nucleic acid or nucleic acid fragment is from Lolium perenne or Lolium arundinaceum. Also disclosed are constructs, plants cells, plants, plant seeds and other plant parts containing said nucleic acids. Also disclosed is a substantially purified or isolated GI polypeptide from a Lolium species. (62) Divided Out of 566723
Patent NZ-584623-A (NZ)
Title: An open faced article storage unit with multiple temperature adjustable shelves
Inventor: WILSON KEVIN
IPC: A47F3/04
Filed: 2010-04-14
Abstract: Disclosed is an open faced merchandiser (10) for storing articles and for maintaining the articles at a specified temperature or within a specified temperature range. The merchandiser comprises of a controller, a plurality of temperature adjustable shelves (11), and at least one sensor. The plurality of shelves support and conduct heat or cold to the articles, and are electrically connected to the controller. The at least one sensor provides feedback to the controller.
Patent NZ-588217-A (NZ)
Title: Spiro-indole derivatives for treating malaria, leishmaniasis and Chagas disease
Inventor: ANG SHI HUA
IPC: A61K31/407
Filed: 2009-04-01
Abstract: The disclosure relates spiro-indole derivatives of formula (I), pharmaceutically acceptable salt or ester thereof, wherein the variables are as defined in the specification. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. These compounds are used for the treatment of parasitic diseases e.g. malaria, leishmaniasis and Chagas disease. The disclosure also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.
Patent NZ-589264-A (NZ)
Title: Process to modify the fiber surface of polymer nonwoven substrates to obtain high density conformal coatings
Inventor: ZHENG YONG
IPC: D06M14/28
Filed: 2009-06-10
Abstract: The disclosure relates to a process for the conformal coating of polymer fibers on nonwoven substrates. This process is based on the modification of polymer fiber surfaces by controlling the degree of etching and oxidation, which improves adhesion of initiators to the surface and facilitates subsequent conformal polymer grafting. The modified fiber surfaces render new functionalities to the surface, such as increasing hydrophilicity, attaching ligands or changing surface energy. Particularly disclosed is a process to modify the fiber surface of a polymer nonwoven substrate to obtain a high density conformal coating, comprising: (a) soaking the substrate with a monomer and an initiator preferably in the presence of a solvent selected from hydrocarbons or alcohols particularly butanol; (b) sandwiching the substrate between two glasses or inserting the substrate into any confined geometry;(c) exposing the substrate to UV for grafting; and (d) washing and drying the substrate; with the proviso that when the polymer nonwoven is polyolefin fiber, then the soaking step is preceded by the step of: increasing the roughness of the fiber surface and increasing the hydroxyl, carbonyl and any other oxygen containing compounds through exposure to UV/ozone.
Patent NZ-589375-A (NZ)
Title: Multilayer film comprising a cross-linked ethylene vinyl acetate layer, an HDPE layer, and a sealant layer.
Inventor: CURIE KEVIN J
IPC: B32B27/32
Filed: 2009-05-28
Abstract: A multilayer film 10 comprises an outer layer comprising a cross-linked ethylene copolymer layer 12, an inner layer 16 comprising a sealant layer and a high density polyethylene (HDPE) layer 14 between the outer layer 12 and the inner layer 16. The multilayer film 10 has a thickness of less than about 2 mils. The multilayer film 10 is oriented by machine direction orientation and exhibits tear strength in the machine direction of at least 40 grams.
Patent NZ-589512-A (NZ)
Title: Arrangement for the transport of wind turbine components where the wind turbine component is connected solely to a support structure
Inventor: POULSEN HENNING
IPC: F03D11/00
Filed: 2010-11-24
Abstract: A system for the transport of wind turbine components 5 with a vehicle comprises at least two wheel sets, a first end frame 1 connected to a first wheel set of the vehicle, a second end frame 3 connected to a second wheel set of the vehicle, and a support structure 2 for carrying at least one wind turbine component. The support structure 2 is connected to at least one of the end frames in a fixed but detachable manner. The wind turbine component 5 is connected solely to the support structure 2 in a fixed but detachable manner. At least one of the wheel sets comprises positioning means for lifting, lowering and turning at least one of the end frames during transport while an end frame is connected to the positioning means.
Patent NZ-590332-A (NZ)
Title: Combination of antibody 224G11 and PF-2341066 for the treatment of cancer
Inventor: GOETSCH LILIANE
IPC: A61K39/395
Filed: 2009-07-08
Abstract: Disclosed is a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal.
Patent NZ-590427-A (NZ)
Title: Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
Inventor: GIULIANI SANDRO
IPC: A61K31/437
Filed: 2009-07-03
Abstract: Disclosed is a pharmaceutical composition comprising, as active ingredients, a corticosteroid and a B2 kinin receptor antagonist, together with pharmaceutically acceptable carriers and excipients, wherein: a.) the corticosteroid, either natural or synthetic, is selected from Cortisone, Hydrocortisone, Beclomethasone, Betamethasone, Budesonide, Dexamethasone, Flumethasone, Flunisolide, Fluocortone, Fluticasone, Methylprednisolone, Methylprednisone, Paramethasone, Prednisolone, Triamcinolone, optionally in the form of an ester with acetic, benzoic, caproic, succinic, phosphoric, propionic or valeric acid, or in the form of acetonide; b.) the B2 kinin receptor antagonist is selected from: - H-D-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-F5F-Igl-Arg-OH; - H-Arg-Arg-Pro-Hyp-Gly-Igl-Ser-D-Igl-Oic-Arg-OH; - H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (Icatibant); - 4-[2-[([[3-(3-Bromo-2-methyl-imidazo[ 1.2-a]pyridine-8-yl oxymethyl)-2,4-dichloro-phenyl]-methyl-carbamoyl]-methy1)carbamoyl]-vinyl]-N,N-dimethyl-benzamide; - 3-(6-Acetylamino-pyridin-3-yl)-N-([[2,4-dichloro-3-(2-methylquinolin-8-yl oxymethyl)-phenyl]-methyl-carbamoyl]-methyl)-acrylamide; -1-[2,4-Dichloro-3-(2,4-dimethy l-quinolin-8-yl oxymethy 1)-benzene sulfonyl]-pyrrolidine-2-carboxylic acid [3-(4-carbamidoyl-benzoylamino )-propyl]-amide (Anatibant); - Bradizide; - 4-( 4-[1-[2,4-Dichloro-3 -(2,4-dimethy l-quinolin-8-y I oxymethy 1)-benzenesulfonyl]-pyrrolidine-2-carbonyl]-piperazine-1-carbonyl)-benzamidine; - 2-[5-(4-Cyano-benzoyl)-1-methyl-1H-pyrrol-2-yl]-N-[2,4-dichloro-3-(2-methly-quinoline-8-yl oxymethyl)-phenyl]-N-methyl-acetamide; -or a compound of general formula (I), wherein the substituents are as described within the specification. Further disclosed is the use of a corticosteroid and a B2 kinin receptor antagonist for the preparation of a medicament for the prevention or therapy of articular and respiratory tract inflammation, lesion and degeneration,
Patent NZ-592688-A (NZ)
Title: Modified blood factors comprising a low degree of water soluble polymer
Inventor: TURECEK PETER
IPC: A61P7/04
Filed: 2009-10-16
Abstract: Disclosed are blood factor 8 molecules with 1-10 polysialic acid moieties and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.
Patent NZ-602271-A (NZ)
Title: Bicyclic compounds and their uses as dual c-src / jak inhibitors
Inventor: MC ALLISTER ANDRES
IPC: A61K31/519
Filed: 2011-02-17
Abstract: ABSTRACT - 602271 The disclosure relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. These compounds are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the transcription factor signal transducer and activator of transcription 3 (STAT3) activation and therefore abnormal growth of particular cell types. Notably, these compounds are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.
Patent NZ-605533-A (NZ)
Title: Immunosuppression modulating compounds
Inventor: SASIKUMAR POTTAYIL GOVINDAN NAIR
IPC: A61P31/00
Filed: 2011-06-27
Abstract: The present disclosure provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present disclosure further provides peptide based compositions for treatment of cancer or treatment of infections via immunepotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the disclosure provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
Patent NZ-609247-A (NZ)
Title: Preservative system for emulsion-based therapeutic topical formulations
Inventor: SPRING NICHOLAS
IPC: A61K31/70
Filed: 2009-10-29
Abstract: The disclosure relates to a topical formulation for treating a lice infestation, comprising an effective amount of an avermectin insecticide dissolved in an oil phase and an aqueous phase comprising one or more preservatives to inhibit the growth of microorganisms. Olive oil is present at a level of about 20% to about 30% by weight of the formulation, and the aqueous phase is buffered with a buffer comprising citric acid and/or sodium citrate to a pH that is from about 4.5 to about 6.2. The oil phase comprises a water-miscible or water-soluble surface active agent, which may comprise polysorbate 80, cetyl acetate, and acetylated lanolin alcohol, olive oil and shea butter as suspending agents, and a non-ionic surfactant selected from the group consisting of: oleyl alcohol, lanolin alcohol, sorbitan tristearate, bees wax, erucyl alcohol, ricinolyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol, behenyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, palmitoleyl alcohol, linoleyl alcohol, elaidyl alcohol, elaidolinoleyl alcohol, linolenyl alcohol, elaidolinolenyl alcohol and combinations thereof. The formulation may exhibit an enhancedresistance to growth of one or more microorganisms selected from the group consisting of Candida albicans, Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.